FoxHollow Announces First Patient Treated With the NightHawk(TM) System, a New Technology Enabling Real-Time Visualization Durin
September 08 2006 - 7:00AM
PR Newswire (US)
REDWOOD CITY, Calif., Sept. 8 /PRNewswire-FirstCall/ -- FoxHollow
Technologies, Inc., (NASDAQ:FOXH), today announced the first-in-man
use of a new technology, which combines onboard real-time imaging
with the SilverHawk(TM) Plaque Excision System. The Company's
latest advance, called NightHawk, brings together optical coherence
tomography (OCT) technology with the FDA-cleared SilverHawk System
to allow for plaque removal in patients suffering from blocked
arteries in the lower legs. The NightHawk technology is currently
being evaluated through a feasibility study at a hospital in
Poland. The first 5 patients were treated at the American Heart of
Poland Hospital in Bielsko this week. A team of U.S. interventional
cardiologists including FoxHollow founder and CEO, Dr. John
Simpson, Dr. Stefan Kiesz and Dr. Greg Robertson attended the
cases. Professor Pawel Buszman is the lead Principal Investigator.
"These initial procedures with the NightHawk, although early-stage,
are very encouraging and consistent with our experience in
pre-clinical studies. They demonstrate the potential for real-time
visualization to enhance procedural results obtained with the
SilverHawk for treating patients suffering from PAD," Simpson
commented. "As a result, we believe the NightHawk may enhance our
ability to treat PAD patients in the near-term and may allow us to
expand the use of our products to other areas of the body." The
NightHawk System utilizes fiber optic technology embedded in the
catheter. While removing plaque, the physician has the ability to
visualize the intravascular placement of the device within the
vessel. Additional advantages of OCT include reductions in the use
of potentially harmful X-Ray imaging and contrast dye which may
present potential risks to patients with pre-existing kidney or
heart conditions. "I was extremely impressed with the performance
of the NightHawk and its ability to provide real-time images inside
the arteries of the lower legs," noted Dr. Greg Robertson. "This
enables the treating physician to visualize target tissue," he
added. Earlier this year, FoxHollow announced a goal of achieving
the first-in- man use of the NightHawk by the end of 2006. After
early success was confirmed in pre-clinical studies, the Company
was able to realize this goal two months prior to the expected
date. About FoxHollow Technologies, Inc. FoxHollow Technologies,
Inc., develops and markets minimally invasive plaque excision
devices for the treatment of peripheral artery disease (PAD). An
estimated 12 million people in the U.S. are thought to suffer from
PAD, with 2.5 million patients currently diagnosed. PAD results
from plaque that accumulates in the arteries and blocks blood flow
in the legs. These blockages can result in severe pain for patients
and very limited physical mobility. The company's SilverHawk system
is a minimally invasive method of removing the obstructive plaque
and restoring blood flow to the legs and feet. For more
information, please visit our website at
http://www.foxhollowtech.com/ . Forward Looking Statements This
press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding FoxHollow's
business that are not historical facts may be "forward-looking
statements" that involve risks and uncertainties. Specifically,
statements concerning the ability of the NightHawk to enhance
treatment of patients with PAD and allow for the use of our
products in other areas of the body are forward-looking statements.
Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks and
uncertainties, which may cause FoxHollow's actual results to differ
materially from the statements contained herein. Risks and
uncertainties are included under the captions, "Managements'
Discussion and Analysis of Financial Condition and Results of
Operations," and "Risk Factors," in our quarterly report on Form
10-Q as filed with the Securities and Exchange Commission on August
9, 2006, which is on file with the SEC and available on our
investor relations website at http://investor.foxhollowtech.com/
and on the SEC's website at http://www.sec.gov/. Undue reliance
should not be placed on forward-looking statements, which speak
only as of the date they are made. FoxHollow undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
they were made, or to reflect the occurrence of unanticipated
events. Contacts: Investor Relations: Matt Ferguson Chief Financial
Officer 650-421-8449 Media Relations: Robin Gaffney 650-421-8614
DATASOURCE: FoxHollow Technologies, Inc. CONTACT: investors, Matt
Ferguson, Chief Financial Officer, +1-650-421-8449, or , or media,
Robin Gaffney, +1-650-421-8614, or , both of FoxHollow
Technologies, Inc. Web site: http://www.foxhollowtech.com/
Copyright
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Aug 2023 to Aug 2024